. Author manuscript; available in PMC: 2023 Oct 1.

Published in final edited form as: J Am Coll Surg. 2022 Sep 15;235(4):592–602. doi: 10.1097/XCS.0000000000000325

Table 3.

Patient Comorbidities from Baseline (pre-MBS) to Long-Term Follow-Up (post-MBS) among Those Who Had Metabolic and Bariatric Surgery at ≤21 Years Old (n=96).

Comorbidityh	Pre-MBS, n (%)	Post-MBS, n (%)	p value^a
Anemia	3 (3.1)	65 (67.7)	<0.001
Asthma	10 (10.4)	0	0.002
Anxiety	7 (7.3)	2 (2.1)	0.169
Back pain	32 (33.3)	4 (4.2)	<0.001
Depression	26 (27.1)	4 (4.2)	<0.001
Diabetes or hyperglycemia	5 (5.2)	0	0.059
GERD	13 (13.5)	3 (3.1)	0.016
Hyperlipidemia	14 (14.6)	0	<0.001
Hypertension	13 (13.5)	1 (1.0)	0.001
Sleep apnea	16 (16.7)	1 (1.0)	<0.001
Transfusion	0	23 (24.0)	<0.001

Fisher’s exact test.

MBS, metabolic and bariatric surgery; GERD, gastroesophageal reflux disease